Liposcience Inc (LPDX) financial statements (2021 and earlier)

Company profile

Business Address 2500 SUMNER BOULEVARD
RALEIGH, NC 27616
State of Incorp. DE
Fiscal Year End December 31
SIC 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2014
Q3
6/30/2014
Q2
3/31/2014
Q1
12/31/2013
Q4
9/30/2013
Q3
6/30/2013
Q2
3/31/2013
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments40434550525455
Cash and cash equivalents40434550525455
Receivables4466777
Inventory, net of allowances, customer advances and progress billings0000000
Inventory0000000
Prepaid expense and other current assets11
Other undisclosed current assets11211  
Total current assets:45485357596263
Noncurrent Assets
Property, plant and equipment17161514131212
Intangible assets, net (including goodwill)1111111
Intangible assets, net (excluding goodwill)1111111
Restricted cash and investments1111112
Deferred costs0000000
Other noncurrent assets00000  
Prepaid expense and other noncurrent assets00
Total noncurrent assets:18181715141414
TOTAL ASSETS:63666972737678
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2122255
Accounts payable2122211
Accrued liabilities     33
Debt42  421
Due to related parties    0  
Other liabilities      0
Other undisclosed current liabilities4419204  
Total current liabilities:9821221076
Noncurrent Liabilities
Long-term debt and lease obligation1213  121315
Long-term debt, excluding current maturities1213  121315
Liabilities, other than long-term debt3333333
Other liabilities3333333
Total noncurrent liabilities:151633151617
Total liabilities:24242324242323
Stockholders' equity
Stockholders' equity attributable to parent39424648495355
Common stock0000000
Additional paid in capital110109109108107106106
Accumulated deficit(71)(67)(63)(61)(58)(53)(51)
Total stockholders' equity:39424648495355
TOTAL LIABILITIES AND EQUITY:63666972737678

Income statement (P&L) ($ in millions)

9/30/2014
Q3
6/30/2014
Q2
3/31/2014
Q1
12/31/2013
Q4
9/30/2013
Q3
6/30/2013
Q2
3/31/2013
Q1
Revenues
(Revenue, Net)
991213131314
Cost of revenue
(Cost of Goods and Services Sold)
(2)(2)(3)(3)(3)(3)(3)
Other undisclosed gross profit   0000
Gross profit:67910101111
Operating expenses(10)(10)(11)(12)(14)(13)(13)
Operating loss:(4)(4)(2)(2)(4)(2)(2)
Nonoperating income0000000
Investment income, nonoperating0000000
Other nonoperating income (expense)   0(0)(0)(0)
Interest and debt expense(0)(0)(0)(0)(0)(0)(1)
Net loss available to common stockholders, diluted:(4)(4)(2)(3)(5)(2)(3)

Comprehensive Income ($ in millions)

9/30/2014
Q3
6/30/2014
Q2
3/31/2014
Q1
12/31/2013
Q4
9/30/2013
Q3
6/30/2013
Q2
3/31/2013
Q1
Net loss:(4)(4)(2)(3)(5)(2)(3)
Comprehensive loss, net of tax, attributable to parent:(4)(4)(2)(3)(5)(2)(3)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: